Literature DB >> 28246893

Crystal arthritides - gout and calcium pyrophosphate arthritis : Part 3: Treatment.

S Schlee1, L C Bollheimer2, T Bertsch3, C C Sieber4,5, P Härle6.   

Abstract

The treatment of gout is based on several principles. Symptom control and termination of the inflammatory process are important early goals, whereas the urate level should be lowered in the long term to prevent further gout attacks and complications. The non-pharmacological approach is based on individually informing the patient on dietary measures and changes of life style. Besides physical measures, such as cold applications on the affected joint, various medications are available for treatment of an acute gout attack. The choice of drug depends on the individual risk profile. If non-steroidal anti-inflammatory drugs (NSAID) and coxibs are chosen it should be taken into account that the use is restricted in patients with renal insufficiency. Moreover, these drugs may have gastrointestinal side effects and are associated with increased cardiovascular morbidity and mortality. Colchicine has gastrointestinal side effects at high dosages but can also be used for differential diagnostics if there is a quick response to treatment. Steroids are an effective alternative and can be given orally or parenterally in patients with dysphagia. Moreover, steroids can be used in cases of renal insufficiency. After symptoms of the acute attack have subsided, urate lowering therapy should be initiated to prevent further attacks. Low-dose urate lowering therapy can be started during an acute gout attack when acute therapy is initiated. Allopurinol is still the medication of choice but its use is restricted in patients with renal insufficiency. A rare but serious side effect is allopurinol hypersensitivity syndrome. Febuxostat can be an alternative in patients who do not tolerate allopurinol. In February 2016, lesinurad, an URAT-1 and OAT-4 inhibitor, was approved in combination with allopurinol or febuxostat. Data on the effectiveness and safety of synthetic uricases and biologicals are still sparse for elderly patients. These substances are reserved for severe cases of gout.

Entities:  

Keywords:  Acute gout flare; Colchicine prophylaxis; Geriatric patients; Parkinson disease; Urate-lowering therapy

Mesh:

Substances:

Year:  2017        PMID: 28246893     DOI: 10.1007/s00391-017-1199-1

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  38 in total

1.  Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.

Authors:  Lisa K Stamp; John L O'Donnell; Mei Zhang; Jill James; Christopher Frampton; Murray L Barclay; Peter T Chapman
Journal:  Arthritis Rheum       Date:  2011-02

2.  2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Authors:  Dinesh Khanna; John D Fitzgerald; Puja P Khanna; Sangmee Bae; Manjit K Singh; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

3.  2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.

Authors:  Dinesh Khanna; Puja P Khanna; John D Fitzgerald; Manjit K Singh; Sangmee Bae; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

4.  EULAR recommendations for calcium pyrophosphate deposition. Part II: management.

Authors:  W Zhang; M Doherty; E Pascual; V Barskova; P-A Guerne; T L Jansen; B F Leeb; F Perez-Ruiz; J Pimentao; L Punzi; P Richette; F Sivera; T Uhlig; I Watt; T Bardin
Journal:  Ann Rheum Dis       Date:  2011-01-20       Impact factor: 19.103

5.  Local ice therapy during bouts of acute gouty arthritis.

Authors:  Naomi Schlesinger; Michelle A Detry; Bart K Holland; Daniel G Baker; Anna M Beutler; Marina Rull; Bruce I Hoffman; H Ralph Schumacher
Journal:  J Rheumatol       Date:  2002-02       Impact factor: 4.666

6.  The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.

Authors:  Michael A Becker; H Ralph Schumacher; Luis R Espinoza; Alvin F Wells; Patricia MacDonald; Eric Lloyd; Christopher Lademacher
Journal:  Arthritis Res Ther       Date:  2010-04-06       Impact factor: 5.156

7.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

Review 8.  The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.

Authors:  S Fahn; G Cohen
Journal:  Ann Neurol       Date:  1992-12       Impact factor: 10.422

9.  Alcohol consumption and the incidence of Parkinson's disease.

Authors:  Miguel A Hernán; Honglei Chen; Michael A Schwarzschild; Alberto Ascherio
Journal:  Ann Neurol       Date:  2003-08       Impact factor: 10.422

10.  Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study.

Authors:  Hyon K Choi; Gary Curhan
Journal:  BMJ       Date:  2008-01-31
View more
  2 in total

1.  Suppressive Effect of Huzhentongfeng on Experimental Gouty Arthritis: An In Vivo and In Vitro Study.

Authors:  Zi-Cong Wu; Qiang Xue; Zhen-Ling Zhao; Peng-Jun Zhou; Qun Zhou; Zhen Zhang; Jian-Ping Deng; Ke Yang; Hua Fan; Yi-Fei Wang; Zhi-Ping Wang
Journal:  Evid Based Complement Alternat Med       Date:  2019-12-04       Impact factor: 2.629

Review 2.  A brief review on in vivo models for Gouty Arthritis.

Authors:  Tulsi Patil; Arun Soni; Sanjeev Acharya
Journal:  Metabol Open       Date:  2021-06-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.